Investigating the efficacy and safety of olanzapine prophylaxis for opioid-induced nausea and vomiting (JORTC-PAL20): a study protocol for an open-label, single-arm exploratory study
Introduction In opioid therapy for cancer pain, opioid-induced nausea and vomiting (OINV) occur in 20%–40% of patients during initial opioid treatment or increasing opioid doses. OINV result in failure to achieve pain relief due to poor opioid adherence. Therefore, antiemetics are used to prevent OI...
Main Authors: | Hiroto Ishiki, Eriko Satomi, Keisuke Ariyoshi, Shunsuke Oyamada, Koji Amano, Ayaka Ishikawa, Sayaka Arakawa, Tomomi Kobayashi, Naomi Sakiyama, Kota Kihara, Akio Mizushima |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/2/e076575.full |
Similar Items
-
Predictors of Morphine Efficacy for Dyspnea in Inpatients with Chronic Obstructive Pulmonary Disease: A Secondary Analysis of JORTC-PAL 07
by: Yoshinobu Matsuda, et al.
Published: (2021-01-01) -
Olanzapine for the prevention and treatment of cancerrelated
nausea and vomiting in adults (Protocol)
by: Sutherland, A, et al.
Published: (2017) -
Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults
by: Sutherland, A, et al.
Published: (2018) -
Clinical Observation of Olanzapine in Treatment of Nausea and Vomiting Caused by Opioid Analgesics
by: LI Daojun, et al.
Published: (2018-05-01) -
The effect and safety of olanzapine on nausea and vomiting in children receiving moderately emetogenic chemotherapy
by: Aziz Eghbali, et al.
Published: (2023-01-01)